New combo therapy shows promise for hard-to-treat breast cancer
NCT ID NCT02734290
First seen Apr 30, 2026 · Last updated May 18, 2026 · Updated 3 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and effective for people with metastatic triple negative breast cancer. About 29 adults with advanced disease that cannot be removed by surgery will receive one of two chemotherapy regimens plus pembrolizumab. The main goals are to track serious side effects and see how many patients can complete six weeks of chemo without major delays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Providence Cancer Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.